Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential

Source The Motley Fool

Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Feb. 19, 2025. The video was published on March 26, 2025.

Should you invest $1,000 in Neurocrine Biosciences right now?

Before you buy stock in Neurocrine Biosciences, consider this:

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Neurocrine Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $739,720!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of March 24, 2025

Karl Thiel has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Silver Price Forecast: XAG/USD surges to record high above $56 amid bullish momentumSilver (XAG/USD) climbs to a fresh all-time high on Friday, buoyed by dovish Federal Reserve expectations alongside strong industrial and investment demand.
Author  FXStreet
Dec 01, Mon
Silver (XAG/USD) climbs to a fresh all-time high on Friday, buoyed by dovish Federal Reserve expectations alongside strong industrial and investment demand.
placeholder
Crypto Market Outlook: Bitcoin, Ethereum, and XRP Tumble as BoJ Hawkishness Sparks Risk-Off RoutBitcoin slides below $87,000, Ethereum leans on $2,800 support and XRP hovers around $2.00 as December opens with a risk-off tone, leaving BTC eyeing $80,600–$74,508, ETH exposed to $2,111 and XRP to $1.90 unless buyers can turn key levels into a base for a rebound.
Author  Mitrade
Dec 01, Mon
Bitcoin slides below $87,000, Ethereum leans on $2,800 support and XRP hovers around $2.00 as December opens with a risk-off tone, leaving BTC eyeing $80,600–$74,508, ETH exposed to $2,111 and XRP to $1.90 unless buyers can turn key levels into a base for a rebound.
placeholder
Fed’s $13.5B Liquidity Injection: Will it Fuel Bitcoin to $50K or Signal a Crash?The Federal Reserve injected $13.5 billion into the banking system, signaling a significant liquidity boost for Bitcoin and risk assets, rivaling levels from the COVID-19 era.
Author  Mitrade
Dec 03, Wed
The Federal Reserve injected $13.5 billion into the banking system, signaling a significant liquidity boost for Bitcoin and risk assets, rivaling levels from the COVID-19 era.
placeholder
Solana Price Forecast: ETF Demand and Derivatives Flows Fuel a Sharper ReboundSolana (SOL) trades above $140 after a 10% daily jump, as ETF inflows flip positive, futures open interest climbs 6.75% and on-chain TVL and stablecoin liquidity rise, setting up a potential double-bottom breakout toward the 50-day EMA at $158 if SOL can secure a daily close above $145.
Author  Mitrade
Dec 03, Wed
Solana (SOL) trades above $140 after a 10% daily jump, as ETF inflows flip positive, futures open interest climbs 6.75% and on-chain TVL and stablecoin liquidity rise, setting up a potential double-bottom breakout toward the 50-day EMA at $158 if SOL can secure a daily close above $145.
placeholder
Avalanche Bulls Eye Trend Reversal, Though Muted Derivatives Signal CautionAvalanche (AVAX) consolidates above $14.00 after an 8% breakout, but with open interest below $600 million and key resistance at $17.14 looming, traders remain cautious.
Author  Mitrade
18 hours ago
Avalanche (AVAX) consolidates above $14.00 after an 8% breakout, but with open interest below $600 million and key resistance at $17.14 looming, traders remain cautious.
goTop
quote